AnaptysBio, Inc. (NASDAQ:ANAB) Director Ecor1 Capital, Llc Purchases 6,646 Shares

AnaptysBio, Inc. (NASDAQ:ANAB) Director Ecor1 Capital, Llc purchased 6,646 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was bought at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the acquisition, the director now owns 7,880,094 shares in the company, valued at $102,047,217.30. The trade was a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Monday, December 30th, Ecor1 Capital, Llc bought 65,184 shares of AnaptysBio stock. The shares were acquired at an average price of $12.92 per share, for a total transaction of $842,177.28.

AnaptysBio Stock Performance

Shares of ANAB traded up $0.12 during trading hours on Thursday, reaching $13.36. 465,990 shares of the company traded hands, compared to its average volume of 390,740. The stock’s fifty day moving average is $20.47 and its 200 day moving average is $28.60. AnaptysBio, Inc. has a 1-year low of $12.51 and a 1-year high of $41.31. The stock has a market cap of $406.53 million, a P/E ratio of -2.20 and a beta of -0.11.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $7.92 million. On average, equities research analysts predict that AnaptysBio, Inc. will post -6.02 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ANAB shares. Guggenheim lowered their price objective on AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. JPMorgan Chase & Co. reduced their price objective on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research note on Thursday, December 19th. BTIG Research downgraded AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. UBS Group increased their price target on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Finally, Truist Financial reduced their price objective on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, AnaptysBio currently has an average rating of “Moderate Buy” and a consensus price target of $41.45.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ANAB. Frazier Life Sciences Management L.P. boosted its holdings in AnaptysBio by 2.0% during the third quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock valued at $74,008,000 after purchasing an additional 43,598 shares in the last quarter. Ensign Peak Advisors Inc lifted its position in shares of AnaptysBio by 74.4% during the 2nd quarter. Ensign Peak Advisors Inc now owns 75,755 shares of the biotechnology company’s stock worth $1,898,000 after buying an additional 32,313 shares during the period. Point72 Asset Management L.P. boosted its stake in AnaptysBio by 202.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 54,200 shares of the biotechnology company’s stock valued at $1,816,000 after buying an additional 36,300 shares in the last quarter. Victory Capital Management Inc. grew its position in AnaptysBio by 677.9% in the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after acquiring an additional 206,750 shares during the period. Finally, Assenagon Asset Management S.A. raised its stake in AnaptysBio by 55.1% during the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after acquiring an additional 168,813 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.